IDYA Stock Overview A synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
IDEAYA Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for IDEAYA Biosciences Historical stock prices Current Share Price US$25.61 52 Week High US$47.74 52 Week Low US$24.48 Beta 0.80 1 Month Change -4.40% 3 Month Change -24.07% 1 Year Change -26.11% 3 Year Change 9.58% 5 Year Change 201.29% Change since IPO 128.87%
Recent News & Updates
IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma Dec 18 Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash Dec 04
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer Nov 18
Consensus revenue estimates decrease by 53%, EPS upgraded Nov 11
Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) Nov 04 See more updates
IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma Dec 18 Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash Dec 04
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer Nov 18
Consensus revenue estimates decrease by 53%, EPS upgraded Nov 11
Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) Nov 04
IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors Oct 28 IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success Sep 20
IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel Sep 18
Consensus revenue estimates fall by 32% Aug 13
First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023) Aug 07
Consensus revenue estimates increase by 10% Jul 15 IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.
Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer? Jul 08
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index Jul 03
Chief Legal Officer & Company Secretary exercised options to buy US$1.9m worth of stock. Jun 28
IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024 Jun 27
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer Jun 25
IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors Jun 24
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality' Jun 18
IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study Jun 05
Chief Scientific Officer notifies of intention to sell stock May 31
IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024 May 29
President notifies of intention to sell stock May 16
Consensus revenue estimates fall by 28% May 14
First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023) May 08
IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024 Apr 21 IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer Mar 12
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment? Feb 22
Price target increased by 12% to US$49.11 Feb 22
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Feb 21
Ideaya Biosciences: A Strong Bet In Targeted Oncology Feb 16
Principal Accounting Officer notifies of intention to sell stock Feb 12
Price target increased by 8.2% to US$43.70 Feb 10
Co-Founder notifies of intention to sell stock Feb 04
Price target increased by 7.7% to US$42.10 Jan 25
New major risk - Shareholder dilution Jan 23 IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Jan 20
Co-Founder notifies of intention to sell stock Jan 15
Co-Founder notifies of intention to sell stock Dec 17
New major risk - Revenue and earnings growth Dec 05
Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week Nov 09
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 09
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline Oct 24
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation Oct 03 IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer
Chief Legal Officer & Company Secretary notifies of intention to sell stock Sep 03
Consensus revenue estimates increase by 25% Aug 20
Price target increased by 7.8% to US$35.08 Aug 18
IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma Aug 17
New major risk - Revenue and earnings growth Aug 12
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Chief Legal Officer & Company Secretary notifies of intention to sell stock Jul 13
IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer Jul 06
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans Jul 04
New major risk - Shareholder dilution Jun 29
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types Jun 13
Chief Legal Officer & Company Secretary exercised options and sold US$64k worth of stock Jun 04
Chief Legal Officer & Company Secretary notifies of intention to sell stock May 26
Consensus revenue estimates increase by 23%, EPS downgraded May 18
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Price target increased by 9.1% to US$28.11 Apr 24
Co-Founder exercised options to buy US$160k worth of stock. Apr 14
We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate Mar 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 08
IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma Jan 24
IDEAYA Biosciences, Inc. Announces Board Appointments Dec 20
IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161 Dec 13
IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline Nov 29
Price target increased to US$23.38 Nov 16
Consensus revenue estimates increase by 85% Nov 16
Price target increased to US$23.38 Nov 11
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 09
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation Nov 04
IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors Oct 19
Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data Oct 06
Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering Sep 14
Price target increased to US$20.57 Sep 12
IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma Sep 12
IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma Sep 07
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate Aug 30
Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials Aug 29
Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2% Aug 25
Consensus revenue estimates fall by 34% Aug 22
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 16
IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M Aug 15
IDEAYA Biosciences, Inc. Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors Jul 28 Shareholder Returns IDYA US Biotechs US Market 7D 1.7% -3.6% -2.4% 1Y -26.1% -2.7% 23.3%
See full shareholder returns
Return vs Industry: IDYA underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: IDYA underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is IDYA's price volatile compared to industry and market? IDYA volatility IDYA Average Weekly Movement 7.4% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: IDYA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IDYA's weekly volatility (7%) has been stable over the past year.
About the Company IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
Show more IDEAYA Biosciences, Inc. Fundamentals Summary How do IDEAYA Biosciences's earnings and revenue compare to its market cap? IDYA fundamental statistics Market cap US$2.21b Earnings (TTM ) -US$178.12m Revenue (TTM ) US$3.92m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IDYA income statement (TTM ) Revenue US$3.92m Cost of Revenue US$193.26m Gross Profit -US$189.34m Other Expenses -US$11.22m Earnings -US$178.12m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.06 Gross Margin -4,827.59% Net Profit Margin -4,541.56% Debt/Equity Ratio 0%
How did IDYA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 03:24 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IDEAYA Biosciences, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Zhiqiang Shu Berenberg Justin Zelin BTIG
Show 22 more analysts 
